MEDICAMEN BIOTECH
|
MEDICAMEN BIOTECH Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 5.16 | 7.47 | 11.64 | 12.19 | 9.93 |
| CEPS(Rs) | 10.71 | 13.05 | 16.67 | 16.92 | 11.99 |
| DPS(Rs) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Book NAV/Share(Rs) | 162.23 | 157.52 | 145.25 | 113.56 | 103.33 |
| Tax Rate(%) | 33.65 | 27.39 | 13.59 | 17.67 | 26.01 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 8.87 | 13.11 | 17.28 | 20.86 | 17.45 |
| EBIT Margin(%) | 8.37 | 10.46 | 14.51 | 17.36 | 15.89 |
| Pre Tax Margin(%) | 6.08 | 7.29 | 12.10 | 15.67 | 14.54 |
| PAT Margin (%) | 4.03 | 5.29 | 10.46 | 12.90 | 10.76 |
| Cash Profit Margin (%) | 8.38 | 9.25 | 14.98 | 17.90 | 13.00 |
| Performance Ratios | |||||
| ROA(%) | 2.24 | 3.34 | 5.87 | 7.11 | 6.46 |
| ROE(%) | 3.23 | 4.94 | 9.13 | 11.25 | 9.89 |
| ROCE(%) | 5.77 | 8.46 | 10.85 | 12.94 | 12.99 |
| Asset Turnover(x) | 0.55 | 0.63 | 0.56 | 0.55 | 0.60 |
| Sales/Fixed Asset(x) | 1.18 | 1.34 | 1.11 | 0.96 | 1.30 |
| Working Capital/Sales(x) | 1.88 | 2.39 | 1.74 | 2.29 | 2.64 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.85 | 0.74 | 0.90 | 1.04 | 0.77 |
| Receivable days | 139.40 | 122.66 | 166.45 | 183.01 | 165.97 |
| Inventory Days | 136.43 | 106.29 | 93.37 | 50.92 | 35.88 |
| Payable days | 226.08 | 215.82 | 311.49 | 316.67 | 253.69 |
| Valuation Parameters | |||||
| PER(x) | 93.43 | 51.31 | 56.31 | 52.79 | 53.78 |
| PCE(x) | 44.96 | 29.37 | 39.31 | 38.05 | 44.53 |
| Price/Book(x) | 2.97 | 2.43 | 4.51 | 5.67 | 5.17 |
| Yield(%) | 0.21 | 0.26 | 0.15 | 0.16 | 0.19 |
| EV/Net Sales(x) | 3.95 | 2.81 | 5.92 | 7.00 | 5.92 |
| EV/Core EBITDA(x) | 31.09 | 19.48 | 31.13 | 31.32 | 32.67 |
| EV/EBIT(x) | 47.24 | 26.85 | 40.82 | 40.35 | 37.27 |
| EV/CE(x) | 2.68 | 2.18 | 3.93 | 3.59 | 3.44 |
| M Cap / Sales | 3.77 | 2.72 | 5.89 | 6.81 | 5.79 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -9.35 | 27.29 | 22.02 | 2.42 | -10.19 |
| Core EBITDA Growth(%) | -20.02 | -3.59 | 3.86 | 26.35 | -4.60 |
| EBIT Growth(%) | -27.45 | -8.27 | 2.00 | 11.90 | -5.32 |
| PAT Growth(%) | -30.95 | -35.54 | -1.14 | 22.82 | -8.74 |
| EPS Growth(%) | -30.95 | -35.86 | -4.53 | 22.82 | -8.74 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.16 | 0.16 | 0.14 | 0.19 | 0.15 |
| Current Ratio(x) | 2.11 | 1.89 | 1.98 | 1.69 | 1.80 |
| Quick Ratio(x) | 1.31 | 1.31 | 1.50 | 1.36 | 1.70 |
| Interest Cover(x) | 3.66 | 3.31 | 6.03 | 10.32 | 11.85 |
| Total Debt/Mcap(x) | 0.06 | 0.06 | 0.03 | 0.03 | 0.03 |
Compare Financial Ratios of peers of MEDICAMEN BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MEDICAMEN BIOTECH | ₹484.3 Cr | 12.2% | 6.6% | -28.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹407,791.0 Cr | 1.2% | 4.2% | -10.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹174,885.0 Cr | -0.5% | 8.9% | 10.8% | Stock Analytics | |
| CIPLA | ₹127,930.0 Cr | 0.4% | 3.7% | 8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹121,108.0 Cr | -0% | -2.1% | 6.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,164.0 Cr | 2.2% | -1.8% | -4.4% | Stock Analytics | |
MEDICAMEN BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MEDICAMEN BIOTECH | 12.2% |
6.6% |
-28.9% |
| SENSEX | 0.9% |
2.5% |
3.7% |
You may also like the below Video Courses
